Ionis Pharmaceuticals Stock Today
| IONS Stock | USD 33.94 1.46 4.12% |
Performance0 of 100
| Odds Of DistressLess than 33
|
Ionis Pharmaceuticals is selling for under 33.94 as of the 22nd of November 2024; that is 4.12 percent decrease since the beginning of the trading day. The stock's lowest day price was 33.63. Ionis Pharmaceuticals has about a 33 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for Ionis Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of May 2024 and ending today, the 22nd of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 17th of May 1991 | Category Healthcare | Classification Health Care |
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California. Ionis Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 157.9 M outstanding shares of which 10.74 M shares are currently shorted by private and institutional investors with about 7.97 trading days to cover. More on Ionis Pharmaceuticals
Moving together with Ionis Stock
| 0.88 | VRAX | Virax Biolabs Group | PairCorr |
| 0.67 | VRPX | Virpax Pharmaceuticals | PairCorr |
| 0.74 | DYN | Dyne Therapeutics | PairCorr |
| 0.76 | XFOR | X4 Pharmaceuticals | PairCorr |
Moving against Ionis Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Ionis Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chairman | Stanley Crooke | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, Dow Jones Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Excise Tax Activities | Animal Testing | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsIonis Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Ionis Pharmaceuticals' financial leverage. It provides some insight into what part of Ionis Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ionis Pharmaceuticals (IONS) is traded on NASDAQ Exchange in USA. It is located in 2855 Gazelle Court, Carlsbad, CA, United States, 92010 and employs 927 people. Ionis Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 5.59 B. Ionis Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 157.9 M outstanding shares of which 10.74 M shares are currently shorted by private and institutional investors with about 7.97 trading days to cover.
Ionis Pharmaceuticals currently holds about 2.04 B in cash with (307.51 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 14.36.
Check Ionis Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationThe majority of Ionis Pharmaceuticals outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Ionis Pharmaceuticals to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Ionis Pharmaceuticals. Please pay attention to any change in the institutional holdings of Ionis Pharmaceuticals as this could imply that something significant has changed or is about to change at the company.
Check Ionis Ownership Details
Ionis Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Pictet Asset Manangement Sa | 2024-06-30 | 2.4 M | |
| Orbimed Advisors, Llc | 2024-06-30 | 2.4 M | |
| Deep Track Capital, Lp | 2024-09-30 | 2.2 M | |
| Clearbridge Advisors, Llc | 2024-06-30 | 2.2 M | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2 M | |
| Macquarie Group Ltd | 2024-06-30 | 1.9 M | |
| Artisan Partners Limited Partnership | 2024-06-30 | 1.7 M | |
| Bvf Inc | 2024-09-30 | 1.5 M | |
| Charles Schwab Investment Management Inc | 2024-09-30 | 1.4 M | |
| Fmr Inc | 2024-09-30 | 22.5 M | |
| Vanguard Group Inc | 2024-09-30 | 15.1 M |
Ionis Pharmaceuticals Historical Income Statement
Ionis Stock Against Markets
Ionis Pharmaceuticals Corporate Management
| Brett Monia | Sr. VP of Drug Discovery and Corporate Devel. | Profile | |
| Patrick Esq | Chief VP | Profile | |
| Eric Swayze | Executive Research | Profile | |
| Hayley Soffer | Vice Communications | Profile |
Additional Tools for Ionis Stock Analysis
When running Ionis Pharmaceuticals' price analysis, check to measure Ionis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ionis Pharmaceuticals is operating at the current time. Most of Ionis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ionis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ionis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ionis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.